J. David Enloe Jr. - 20 Jan 2022 Form 4 Insider Report for Recro Pharma, Inc.

Role: Chief Executive Officer, Director
Signature: By: Ryan D Lake, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 20 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 24 Jan 2022, 20:27:21 UTC
Previous filing: 19 Jan 2022
Next filing: 17 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SCTL	Common Stock	Award		+66,007	+43%		220,766	20 Jan 2022	Direct	F1
transaction	SCTL	Common Stock	Award	$0	+303,030	+137%	$0.000000	523,796	20 Jan 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SCTL	Stock Option (Right to Buy)	Award	$0	+442,478		$0.000000	442,478	20 Jan 2022	Common Stock	442,478	$1.65	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 20, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 66,007 performance-based restricted stock units granted in a prior year, which were converted into 66,007 shares of common stock on a one-for-one basis.
F2	These restricted stock units will vest in four equal annual installments beginning on January 20, 2023, subject to continued service with the Company.
F3	The stock option vests in equal monthly installments over 48 months, beginning on February 20, 2022, subject to continued service with the Company.